Oral anticoagulation reduces thromboembolic events associated with atrial fibrillation, yet 50% of patient with atrial fibrillation are not prescribed anticoagulants. Recent studies, including our preliminary findings, showed significant racial disparities in the prescribing of anticoagulants even after accounting for access to care, health insurance, and stroke risk factors. In this study, we will evaluate new factors that explain anticoagulant under-prescription, racial disparities in the prescription of anticoagulants, and incidence of stroke among patients newly diagnosed with atrial fibrillation.
Yacob Tedla, PhD
Funding for this project is provided by Bristol-Myers Squibb and Pfizer. Grant Number: CV185-767.
2020 – 2022
CHIP collaborators are part of the public, private and nonprofit sectors and have an interest in working toward a world where health outcomes are improved because data is used effectively.Get in Touch